Evaluation of Lumipulse® G1200 for the measurement of six tumor markers: Comparison with AIA® 2000

Clin Biochem. 2016 Nov;49(16-17):1302-1306. doi: 10.1016/j.clinbiochem.2016.08.003. Epub 2016 Aug 10.

Abstract

Tumor marker assays are daily practiced, for screening and follow up of cancers. Interassay precision is an important parameter for the interpretation of the kinetics of the markers, in order to conclude to the efficiency or failure of treatment. The aim of this study was to compare two automated Immunoassay analyzers, Lumipulse® G1200 and AIA® 2000. Both analyzers used an immunoassay system but with different antibodies. Six tumor markers commonly used were studied: AFP, PSA, CA 19-9, CA 15-3, CA 125 and CEA. 253 samples have been collected over a period of one month and analyzed by both analyzers. Regression of Passing-Badblock and Bland-Altman diagram were used to analyze the results for AFP (n=36), PSA (n=39), CA-125 (n=40), CA 15-3 (n=40), CA 19-9 (n=46) and CEA (n=52) were performed. Analytical performances of Lumipulse® G1200 highlighted the good inter-run and intra-run precision of the analyzer. We obtained a good correlation coefficient between Lumipulse G1200® and AIA 2000®, >0.96 for most markers except CA 19-9 which provided a correlation coefficient significantly lower than that obtained with other markers. The concordance for all markers was >94% except for CA 19-9 (83.7%). This study showed a good correlation between the two analyzers and, therefore, a transfer from one analyzer to the other is possible for the different markers studied. However, we found here the classical difficulty to transfer this type of analysis, due to the absence of method standardization. This difficulty was particularly illustrated by CA19-9.

Keywords: AIA® 2000; Chemiluminescence; Evaluation; LUMIPULSE® G1200; Tumor markers.

Publication types

  • Comparative Study

MeSH terms

  • Biomarkers, Tumor / blood*
  • Humans
  • Immunoassay / methods*
  • Neoplasms / diagnosis

Substances

  • Biomarkers, Tumor